Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

Authors Juul J, Mullins C, Peppard WJ, Huang A

Received 1 November 2015

Accepted for publication 18 January 2016

Published 16 February 2016 Volume 2016:12 Pages 225—232

DOI https://doi.org/10.2147/TCRM.S71855

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jingyi Li

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


Janelle J Juul, Caitlin F Mullins, William J Peppard, Angela M Huang

Department of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA

Abstract: Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 week. Two multinational, identically designed, non-inferiority trials, DISCOVER 1 and 2, demonstrated similar early clinical success with dalbavancin compared to vancomycin with an option to switch to oral linezolid. In a recently published non-inferiority trial, a single-dose regimen of dalbavancin was compared to the traditional two-dose administration and was found to have a non-inferior clinical response. In the aforementioned trials, dalbavancin was well tolerated, with patients experiencing transient adverse events of mild to moderate severity. The prolonged half-life, excellent skin and soft tissue penetration, bactericidal activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, and convenient dosing make dalbavancin a reasonable option for the treatment of acute bacterial skin and skin structure infections in adult patients who have tried and failed other therapies.

Keywords: acute bacterial skin and skin structure infections, skin and soft tissue infections, dalbavancin, glycopeptide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]